Alpha Capital被任命为CD8技术服务公司5 000M设施开发的财务顾问,用于建立细胞治疗GMP能力。 Alpha Capital appointed as financial advisor for CD8 Technology Services' $50M facility development for cell therapy GMP capabilities.

Alpha Capital被指定为CD8技术服务局的独家财务顾问。 CD8技术服务局正在寻求高达5 000万美元的资金,以开发一个与细胞治疗有关的生物产品制造设施。 Alpha Capital has been appointed as the exclusive financial advisor for CD8 Technology Services, which is seeking up to $50 million to develop a facility for biologic product manufacturing related to cell therapy. 这一设施旨在加强全球监测方案的能力,加快客户的制造,包括Tevogen Bio,后者计划利用它发展现成的传染病和癌症T细胞疗法。 This facility aims to enhance GMP capabilities and expedite manufacturing for clients, including Tevogen Bio, which plans to utilize it for developing off-the-shelf T-cell therapies for infectious diseases and cancers.